Zhang Guoqing, Yan Beibei, Guo Yanan, Yang Hang, Li Jindong
Department of Thoracic Surgery and Lung Transplantation, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2022 Jul 8;12:952939. doi: 10.3389/fonc.2022.952939. eCollection 2022.
TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon mutations that are insensitive to TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at different sites, and a combination regimen for delaying/preventing resistance to targeted therapy or obtaining more intensive inhibition for uncommon mutations at cellular, animal and human levels has been explored. This review critically focuses on a combination strategy for uncommon mutation-positive NSCLC, and discuss the preclinical data, clinical implications, limitations and future prospects of the combination strategy.
酪氨酸激酶抑制剂（TKIs）并非治愈性药物，靶向耐药不可避免地导致治疗失败。此外，存在许多对TKIs不敏感的罕见突变，且缺乏克服这些局限性的临床策略。表皮生长因子受体（EGFR）酪氨酸激酶抑制剂和单克隆抗体在不同位点靶向EGFR，人们已在细胞、动物和人体水平探索了联合用药方案，以延缓/预防靶向治疗耐药或对罕见突变获得更强抑制作用。本综述重点关注罕见突变阳性非小细胞肺癌（NSCLC）的联合治疗策略，并讨论该联合治疗策略的临床前数据、临床意义、局限性及未来前景。
